Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles

Biomaterials

Volumn 32, Issue 28, 2011, Pages 6860-6874

  Swarnakar, Nitin K ^a   Jain, Amit K ^a   Singh, Raman P ^a   Godugu, Chandraiah ^a   Das, Manasmita ^a   Jain, Sanyog ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Anti inflammatory activity; CoQ10; Hepatoprotective activity; Mitochondria and lysosomes localization; Oxidative stress; PLGA nanoparticles

Indexed keywords

ANIMAL IMAGING; ANTI-INFLAMMATORY ACTIVITY; COENZYME Q10; COQ10; CRYSTALLINITIES; DELETERIOUS EFFECTS; HEPATOPROTECTIVE; IN-VITRO; PLGA NANOPARTICLES; POLYMERIC NANOPARTICLES; POSITIVELY CHARGED; REACTIVE OXYGEN SPECIES; ROOM TEMPERATURE; SCAVENGING PROPERTIES; THERAPEUTIC EFFICACY;

ANIMAL CELL CULTURE; BIOCHEMISTRY; EMULSIFICATION; FREE RADICALS; FUNCTIONAL POLYMERS; MITOCHONDRIA; TISSUE;

NANOPARTICLES;

NANOPARTICLE; POLYGLACTIN; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; UBIDECARENONE NANOPARTICLE CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFUSION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; EMULSION; EVAPORATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER PROTECTION; LYSOSOME; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; THERMAL ANALYSIS;

ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; FEMALE; FREEZE DRYING; HUMANS; INFLAMMATION; MATERIALS TESTING; MICE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; THIOBARBITURIC ACID REACTIVE SUBSTANCES; UBIQUINONE; X-RAY DIFFRACTION;

ANIMALIA;

EID: 79960556005     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.05.079     Document Type: Article

References (57)

1. Bonakdar R.A., Guarneri E. Coenzyme Q10. Am Fam Physician 2005, 72(6):1065-1070.
2. Aberg F., Appelkvist E.L., Broijersen A., Eriksson M., Angelin B., Hjemdahl P., et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia. Eur J Clin Invest 1998, 28(3):235-242.
3. Parikh S., Saneto R., Falk M.J., Anselm I., Cohen B.H., Haas R., et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol 2009, 11(6):414-430.
4. Al Gadban M.M., Smith K.J., Soodavar F., Piansay C., Chassereau C., Twal W.O., et al. Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress. PLoS One 2010, 5(9):e12534.
5. Littarru G.P., Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 2007, 37(1):31-37.
6. Hodgson J.M., Watts G.F., Playford D.A., Burke V., Croft K.D. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002, 56:1137-1142.
7. Bhagavan H.N., Chopra R.K. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 2006, 40(5):445-453.
8. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997, 41(2):160-165.
9. Safarinejad M.R. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study. Int J Impot Res 2010, 22:298-309.
10. Borekova M., Hojerova J., Koprda V., Bauerova K. Nourishing and health benefits of coenzyme Q10-a review. Czech J Food Sci 2008, 26(4):229-241.
11. Takada M., Yuzuriha T., Katayama K., Yamato C., Koyama N. Targeting of coenzyme Q10 solubilized with soy lecithin to heart of guinea pigs. J Nutr Sci Vitaminol 1985, 31(1):115-120.
12. Kimura A., Yamaguchi H., Watanabe K., Hayashi M., Awazu S. Factors influencing the tissue distribution of coenzyme Q10 intravenously administered in an emulsion to rats: emulsifying agents and lipoprotein lipase activity. J Pharm Pharmacol 1986, 38(9):659-662.
13. Takeuchi H., Sasaki H., Niwa T., Hino T., Kawashima Y., Uesugi K., et al. Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int J Pharm 1992, 86(1):25-33.
14. Terao K., Nakata D., Fukumi H., Schmid G., Arima H., Hirayama F., et al. Enhancement of oral bioavailability of coenzyme Q10 by complexation with [gamma]-cyclodextrin in healthy adults. Nutr Res 2006, 26(10):503-508.
15. Gokce E.H., Ozyazici M., Souto E.B. Nanoparticulate strategies for effective delivery of poorly soluble therapeutics. Ther Deliv 2010, 1(1):149-167.
16. Bhandari K.H., Newa M., Kim J.A., Yoo B.K., Woo J.S., Lyoo W.S., et al. Preparation, characterization and evaluation of coenzyme Q10 binary solid dispersions for enhanced solubility and dissolution. Biol Pharm Bull 2007, 30(6):1171-1176.
17. Kommuru T.R., Gurley B., Khan M.A., Reddy I.K. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm 2001, 212(2):233-246.
18. Nehilla B.J., Bergkvist M., Popat K.C., Desai T.A. Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles. Int J Pharm 2008, 348(1-2):107-114.
19. Bhagavan H.N., Chopra R.K. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 2007, 7:S78-S88.
20. Miles M.V. The uptake and distribution of coenzyme Q (10). Mitochondrion 2007, 7:S72-S77.
21. Bentinger M., Dallner G., Chojnacki T., Swiezewska E. Distribution and breakdown of labeled coenzyme Q10 in rat. Free Radic Biol Med 2003, 34(5):563-575.
22. Murphy M.P., Smith R.A.J. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007, 24:629-656.
23. Murphy M.P. Targeting lipophilic cations to mitochondria. Biochim Biophys Acta Bioenerg 2008, 1777(7-8):1028-1031.
24. Jain A.K., Das M., Swarnakar N.K., Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst 2011, 28(1):1-45.
25. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A.G., Ithakissios D.S. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Rel 2002, 79(1-3):123-135.
26. Govender T., Stolnik S., Garnett M.C., Illum L., Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Rel 1999, 57(2):171-185.
27. Kalaria D.R., Sharma G., Beniwal V., Ravi Kumar M.N. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 2009, 26(3):492-501.
28. Song C.X., Labhasetwar V., Murphy H., Qu X., Humphrey W.R., Shebuski R.J., et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Rel 1997, 43(2-3):197-212.
29. Jain A.K., Swarnakar N.K., Godugu C., Singh R.P., Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011, 32:503-515.
30. Ankola D.D., Viswanad B., Bhardwaj V., Ramarao P., Kumar M.N.V. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?. Eur J Pharm Biopharm 2007, 67(2):361-369.
31. Jain S., Mittal A., Jain A.K., Mahajan R.R., Singh D. Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in vitro characterization and stability studies. Curr Nanoscience 2010, 6(4):422-431.
32. Zimmermann E., Müller R.H. Electrolyte-and pH-stabilities of aqueous solid lipid nanoparticle (SLN (TM)) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm 2001, 52(2):203-210.
33. Abdelwahed W., Degobert G., Fessi H. Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. Eur J Pharm Biopharm 2006, 63(2):87-94.
34. Nakajima M., Takeuchi T., Morimoto K. Determination of 8-hydroxydeoxyguanosine in human cells under oxygen-free conditions. Carcinogenesis 1996, 17(4):787-791.
35. Min Y.S., Lee S.E., Hong S.T., Kim H.S., Choi B.C., Sim S.S., et al. The inhibitory effect of quercetin-3-O-b-D-glucuronopyranoside on gastritis and reflux esophagitis in rats. Auton Autacoid Pharmacol 2009, 25:85-91.
36. ®. J Control Rel 2007, 119(2):197-206.
37. Morris C.J. Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol 2003, 225:115-121.
38. Winter C.A., Risley E.A., Nuss G.W. Carrageen ininduced edema in hind paws of the rat as an assay for anti-iflammatory drugs. Proc Soc Exp Biol Med 1962, 111:544-547.
39. Yuan J.P., Liang B.L., Deng H.R., Liu Z.S., Bai S.M., Zhong J.L. Adenovirus mediated gene transfer of tyrosinase gene on HepG2 cell by magnetic resonance imaging. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2009, 31(2):146-150.
40. Keyaerts M., Verschueren J., Bos T.J., Tchouate-Gainkam L.O., Peleman C., Breckpot K., et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008, 35(5):999-1007.
41. Prabha S., Zhou W.Z., Panyam J., Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 2002, 244(1-2):105-115.
42. Jain A.K., Goyal A.K., Mishra N., Vaidya B., Mangal S., Vyas S.P. PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B. Int J Pharm 2010, 387(1-2):253-262.
43. Cherng S.C., Cheng S.N., Tarn A., Chou T.C. Anti-inflammatory activity of c-phycocyanin in lipopolysaccharide-stimulated RAW 264.7 macrophages. Life Sci 2007, 81(19-20):1431-1435.
44. Murphy M.P., Smith R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 2000, 41(2):235-250.
45. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55(3):329-347.
46. O'Neill P.M., Bray P.G., Hawley S.R., Ward S.A., Park B.K. 4-Aminoquinolines-past, present, and future: a chemical perspective. Pharmacol Ther 1998, 77(1):29-58.
47. Cho J.Y. Chloroquine, an anti-malarial agent, acts as a novel regulator of beta 1-integrin-mediated cell-cell adhesion. Biol Pharm Bull 2008, 31(4):726-730.
48. Van Oost B.A., Smith J.B., Holmsen H., Vladutiu G.D. Lysosomotropic agents selectively potentiate thrombin-induced acid hydrolase secretion from platelets. Proc Natl Acad Sci 1985, 82(8):2374-2378.
49. Kubota C., Torii S., Hou N., Saito N., Yoshimoto Y., Imai H., et al. Constitutive reactive oxygen species generation from autophagosome/lysosome in neuronal oxidative toxicity. J Biol Chem 2010, 285(1):667-674.
50. Nakanishi H., Wu Z. Microglia-aging: roles of microglial lysosome-and mitochondria-derived reactive oxygen species in brain aging. Behav Brain Res 2009, 201(1):1-7.
51. Mohs A.M., Duan H., Kairdolf B.A., Smith A.M., Nie S. Proton-resistant quantum dots: stability in gastrointestinal fluids and implications for oral delivery of nanoparticle agents. Nano Res 2009, 2(6):500-508.
52. Deacon M.P., McGurk S., Roberts C.J., Williams P.M., Tendler S.J., Davies M.C., et al. Atomic force microscopy of gastric mucin and chitosan mucoadhesive systems. Biochem J 2000, 348(Pt 3):557-563.
53. Amimoto T., Matsura T., Koyama S.Y., Nakanishi T., Yamada K., Kajiyama G. Acetaminophen-induced hepatic injury in mice: the role of lipid peroxidation and effects of pretreatment with coenzyme Q10 and alpha-tocopherol. Free Radic Biol Med 1995, 19(2):169-176.
54. Matsura T., Yamada K., Kawasaki T. Difference in antioxidant activity between reduced coenzyme Q9 and reduced coenzyme Q10 in the cell: studies with isolated rat and guinea pig hepatocytes treated with a water-soluble radical initiator. Biochim Biophys Acta 1992, 1123(3):309-315.
55. Jung H.J., Park E.H., Lim C.J. Evaluation of anti angiogenic, anti inflammatory and antinociceptive activity of coenzyme Q10 in experimental animals. J Pharm Pharmacol 2009, 61(10):1391-1395.
56. Wang X.M., Hamza M., Wu T.X., Dionne R.A. Upregulation of IL-6, IL-8 and CCL2 gene expression after acute inflammation: correlation to clinical pain. Pain 2009, 142(3):275-283.
57. 2 release by adherent neutrophil leukocytes. J Immunol 1995, 154(3):1383-1390.